A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson’s disease

[1]  G. Banker,et al.  Axonal transport plays a crucial role in mediating the axon-protective effects of NmNAT , 2014, Neurobiology of Disease.

[2]  Sang Ki Park,et al.  CDK5-dependent inhibitory phosphorylation of Drp1 during neuronal maturation , 2014, Experimental & Molecular Medicine.

[3]  J. Gilley,et al.  Wallerian degeneration: an emerging axon death pathway linking injury and disease , 2014 .

[4]  G. Le Douaron,et al.  MALDI Mass Spectrometry Imaging of 1-Methyl-4-phenylpyridinium (MPP+) in Mouse Brain , 2013, Neurotoxicity Research.

[5]  M. Shamloo,et al.  Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. , 2013, The Journal of clinical investigation.

[6]  J. Viovy,et al.  NAD+ acts on mitochondrial SirT3 to prevent axonal caspase activation and axonal degeneration , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  N. Unsain,et al.  XIAP regulates caspase activity in degenerating axons. , 2013, Cell reports.

[8]  Jean-Louis Viovy,et al.  Synapto-Protective Drugs Evaluation in Reconstructed Neuronal Network , 2013, PloS one.

[9]  Lauren E. Marbella,et al.  Observing the translocation of a mitochondria-penetrating peptide with solid-state NMR. , 2013, Biochimica et biophysica acta.

[10]  J. Qian,et al.  MAVS-mediated host cell defense is inhibited by Borna disease virus. , 2013, The international journal of biochemistry & cell biology.

[11]  J. Ramsey,et al.  Distinct Pathways Mediate Axon Degeneration during Apoptosis and Axon-Specific Pruning , 2013, Nature Communications.

[12]  M. Iijima,et al.  Mitochondrial dynamics in neurodegeneration. , 2013, Trends in cell biology.

[13]  P. Wipf,et al.  Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. , 2012, Cell reports.

[14]  A. M. van der Bliek,et al.  Mitochondrial Fission, Fusion, and Stress , 2012, Science.

[15]  Christian Haass,et al.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences , 2012, The EMBO journal.

[16]  C. Perier,et al.  Neurotoxin-based models of Parkinson's disease , 2012, Neuroscience.

[17]  J. Milbrandt,et al.  Mitofusin2 Mutations Disrupt Axonal Mitochondrial Positioning and Promote Axon Degeneration , 2012, The Journal of Neuroscience.

[18]  E. Rugarli,et al.  Mitochondrial quality control: a matter of life and death for neurons , 2012, The EMBO journal.

[19]  L. Scorrano,et al.  Less than perfect divorces: dysregulated mitochondrial fission and neurodegeneration , 2012, Acta Neuropathologica.

[20]  R. Barker,et al.  A novel neuroprotective therapy for Parkinson’s disease using a viral noncoding RNA that protects mitochondrial Complex I activity , 2012, The Journal of experimental medicine.

[21]  W. Lipkin,et al.  Borna disease virus - fact and fantasy. , 2011, Virus research.

[22]  Bhuvan Unhelkar,et al.  Strategies and Applications , 2011 .

[23]  J. Milbrandt,et al.  Image-based Screening Identifies Novel Roles for IκB Kinase and Glycogen Synthase Kinase 3 in Axonal Degeneration* , 2011, The Journal of Biological Chemistry.

[24]  Bruce H. Morimoto,et al.  A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions , 2011, Molecular and Cellular Neuroscience.

[25]  S. Kelley,et al.  Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells. , 2011, Journal of the American Chemical Society.

[26]  Y. Yoon,et al.  High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. , 2011, Antioxidants & redox signaling.

[27]  R. Sobel,et al.  Aberrant mitochondrial fission in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo , 2011, Molecular biology of the cell.

[28]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[29]  Jean-Louis Viovy,et al.  Wallerian-Like Degeneration of Central Neurons After Synchronized and Geometrically Registered Mass Axotomy in a Three-Compartmental Microfluidic Chip , 2010, Neurotoxicity Research.

[30]  M. Delepierre,et al.  Attenuation of Rabies Virulence: Takeover by the Cytoplasmic Domain of Its Envelope Protein , 2010, Science Signaling.

[31]  J. Gilley,et al.  Endogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons , 2010, PLoS biology.

[32]  J. Chuckowree,et al.  Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system , 2009, Brain Research Bulletin.

[33]  S. Kelley,et al.  Mitochondria‐Penetrating Peptides: Sequence Effects and Model Cargo Transport , 2009, Chembiochem : a European journal of chemical biology.

[34]  S. Kelley,et al.  Targeting Mitochondria with Organelle‐Specific Compounds: Strategies and Applications , 2009, Chembiochem : a European journal of chemical biology.

[35]  P. Staeheli,et al.  Second-site mutations in Borna disease virus overexpressing viral accessory protein X. , 2009, The Journal of general virology.

[36]  E. Morselli,et al.  Targeting post-mitochondrial effectors of apoptosis for neuroprotection. , 2009, Biochimica et biophysica acta.

[37]  G. Bauer,et al.  Protein X of Borna Disease Virus Inhibits Apoptosis and Promotes Viral Persistence in the Central Nervous Systems of Newborn-Infected Rats , 2009, Journal of Virology.

[38]  N. Udupa,et al.  A study of rivastigmine liposomes for delivery into the brain through intranasal route , 2008, Acta pharmaceutica.

[39]  E. Morselli,et al.  Viral Control of Mitochondrial Apoptosis , 2008, PLoS pathogens.

[40]  T. Langer,et al.  Quality control of mitochondria: protection against neurodegeneration and ageing , 2008, The EMBO journal.

[41]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[42]  Toshihiko Oka,et al.  Mitotic Phosphorylation of Dynamin-related GTPase Drp1 Participates in Mitochondrial Fission* , 2007, Journal of Biological Chemistry.

[43]  P. Staeheli,et al.  The X Protein of Borna Disease Virus Serves Essential Functions in the Viral Multiplication Cycle , 2007, Journal of Virology.

[44]  S. Przedborski,et al.  Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.

[45]  J. Milbrandt,et al.  Stimulation of Nicotinamide Adenine Dinucleotide Biosynthetic Pathways Delays Axonal Degeneration after Axotomy , 2006, The Journal of Neuroscience.

[46]  D. Chan.  Mitochondria: Dynamic Organelles in Disease, Aging, and Development , 2006, Cell.

[47]  R. G. Thorne,et al.  Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration , 2004, Neuroscience.

[48]  T. Wolff,et al.  The X protein of Borna disease virus regulates viral polymerase activity through interaction with the P protein. , 2004, The Journal of general virology.

[49]  E. Perret,et al.  Persistent, non‐cytolytic infection of neurons by Borna disease virus interferes with ERK 1/2 signaling and abrogates BDNF‐induced synaptogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  S. Münter,et al.  Borna Disease Virus Glycoprotein Is Required for Viral Dissemination in Neurons , 2003, Journal of Virology.

[51]  Jia Luo,et al.  Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model , 2002, Science.

[52]  John T. Finn,et al.  Axonal Self-Destruction and Neurodegeneration , 2002, Science.

[53]  K. Ikuta,et al.  Molecular and cellular biology of Borna disease virus infection. , 2002, Microbes and infection.

[54]  T. Sherer,et al.  Complex I and Parkinson's Disease , 2001, IUBMB life.

[55]  D. German,et al.  The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[56]  M. Herkenham,et al.  Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study , 1991, Neuroscience.

[57]  W. Nicklas,et al.  IV. MPTP, MPP+ and mitochondrial function , 1987 .

[58]  R. Prediger,et al.  Evaluation of Nigrostriatal Neurodegeneration and Neuroinflammation Following Repeated Intranasal 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice, an Experimental Model of Parkinson’s Disease , 2013, Neurotoxicity Research.

[59]  M. Lafon.  Evasive strategies in rabies virus infection. , 2011, Advances in virus research.

[60]  R. Abagyan,et al.  Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. , 2007, Science.

[61]  R. Fujinami,et al.  Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis: When can axonal injury be beneficial? , 2007, The American journal of pathology.

[62]  W. Nicklas,et al.  MPTP, MPP+ and mitochondrial function. , 1987, Life sciences.